Harmony Biosciences Projects 2026 WAKIX Revenue Between $1.00B and $1.04B Amid CEO Transition
Harmony Biosciences (HRMY) has provided long-term revenue guidance for its product WAKIX, projecting annual net revenue to fall between $1.00 billion and $1.04 billion in 2026. This projection underscores the company's growth trajectory and the commercial importance of its core product line. Alongside these financial projections, the company announced a leadership transition. The current CEO will step down at the end of the year, with Peter Anastasiou, currently Senior Executive Vice President and Chief Operating Officer, slated to take over as President and Chief Executive Officer effective January 2027.
Tickers: $HRMY